Reporting by Ludwig Burger; editing by Matthias Williams
/cloudfront-us-east-2.images.arcpublishing.com/reuters/56X4QQ6MY5IHFCPDVCREVKJT2M.jpg)
The logo of BioNTech is pictured at Biontech’s research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay/ File photo Acquire Licensing Rights
FRANKFURT, Nov 21 (Reuters) – COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna (MRNA.O) in litigation about alleged an patent violation by BioNTech and its partner Pfizer (PFE.N).
“We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1,” the German biotech firm said in a statement.
“The European Patent Office’s decision is an important one as we believe that this and others of Moderna’s patents do not meet the requirements for grant and should never have been granted,” it added.
Reporting by Ludwig Burger; editing by Matthias Williams
Our Standards: The Thomson Reuters Trust Principles.
DORMAGEN, Germany, Nov. 29, 2023 /PRNewswire/ -- DN Solutions is taking its customer support in Europe to a new level: with the opening of its first Technical
Net earnings were $819.2 million, or $0.85 per diluted share for the second quarter of fiscal 2024 compared with $810.4 million, or $0.79 per diluted share fo
A coalition of artist and label groups is calling on legislators to urgently address a 2020 court ruling that risks seeing European musicians lose out on mill
